Modafinil

Generic Name
Modafinil
Brand Names
Provigil
Drug Type
Small Molecule
Chemical Formula
C15H15NO2S
CAS Number
68693-11-8
Unique Ingredient Identifier
R3UK8X3U3D
Background

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...

Indication

To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
Associated Therapies
-
Clinical Trials
Related News

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

First Posted Date
2016-08-05
Last Posted Date
2017-12-12
Lead Sponsor
University of Chicago
Registration Number
NCT02857244
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

A Study of LY3154207 on Sleep in Healthy Male Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: LY3154207
Drug: Modafinil
First Posted Date
2015-11-13
Last Posted Date
2016-04-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
16
Registration Number
NCT02603861
Locations
🇺🇸

Parexel Early Phase Unit at Glendale, Glendale, California, United States

Complementary Combination Therapy for Cocaine Dependence

First Posted Date
2015-09-02
Last Posted Date
2022-04-26
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
45
Registration Number
NCT02538744
Locations
🇺🇸

Michael Debakey VA Medical Center, Houston, Texas, United States

Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea

First Posted Date
2015-07-10
Last Posted Date
2019-06-20
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
105
Registration Number
NCT02494102
Locations
🇺🇸

Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study

Phase 4
Conditions
Fatigue
Interventions
Drug: Modafinil
First Posted Date
2015-03-11
Last Posted Date
2015-03-11
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
20
Registration Number
NCT02385656
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Pain Expectations in Subjects With Osteoarthritis

Phase 4
Completed
Conditions
Osteoarthritis
Interventions
Drug: Placebo
Drug: Modafinil
Drug: Gabapentin
First Posted Date
2014-06-04
Last Posted Date
2019-03-07
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
30
Registration Number
NCT02155257
Locations
🇺🇸

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States

Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls

First Posted Date
2014-01-31
Last Posted Date
2014-01-31
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Target Recruit Count
64
Registration Number
NCT02051153
Locations
🇬🇧

Department of Psychiatry, Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, United Kingdom

Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill

Phase 3
Withdrawn
Conditions
Delirium
Respiratory Failure
Interventions
Drug: Placebo
Drug: Modafinil
First Posted Date
2014-01-07
Last Posted Date
2016-11-03
Lead Sponsor
Brigham and Women's Hospital
Registration Number
NCT02028260
Locations
🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Modafinil and Cognitive Function in POTS

Early Phase 1
Active, not recruiting
Conditions
Postural Tachycardia Syndrome
Interventions
Drug: Placebo
Drug: Modafinil
Drug: Propranolol
First Posted Date
2013-11-20
Last Posted Date
2024-02-01
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
20
Registration Number
NCT01988883
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
Drug: Modafinil
First Posted Date
2013-10-18
Last Posted Date
2018-03-21
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
18
Registration Number
NCT01965925
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy